The present study aims to elucidate the predictive value of short-term serial quantitative assessment of KRAS-mutated ctDNA values at initial first-line chemotherapy to identify a reliable indicator of therapeutic response in patients with treatment-resistant advanced pancreatic cancer. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.